Farletuzumab
- Generic Name
- Farletuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 896723-44-7
- Unique Ingredient Identifier
- 2O09BG0OWA
- Background
Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.
- Indication
Investigated for use/treatment in ovarian cancer.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT02289950
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
- Conditions
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2013-11-03
- Lead Sponsor
- Morphotek
- Registration Number
- NCT01203618
- Locations
- ๐บ๐ธ
Emory University, Atlanta, Georgia, United States
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
- Conditions
- Interventions
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 1100
- Registration Number
- NCT00849667
- Locations
- ๐บ๐ธ
Hematology Oncology P.C., Stamford, Connecticut, United States
๐บ๐ธLoyola University Chicago, Maywood, Illinois, United States
๐บ๐ธMercy Medical Center, Baltimore, Maryland, United States
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 58
- Registration Number
- NCT00318370
- Locations
- ๐บ๐ธ
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
๐บ๐ธHematology and Oncology Specialists, LLC, Metarie, Louisiana, United States
๐บ๐ธThe Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.